Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

Summary

The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: Does CP-383 slow or stop the growth of cancer in patients with advanced cancer What medical problems do participants have when taking CP-383 Researchers will test CP-383 in all kinds of cancers at various dose levels to determine what the best dose is to study further.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Solid Tumor Malignancies
• Colorectal Carcinoma
• Small Cell Lung Cancer ( SCLC )
• Head and Neck (HNSCC)
• Bladder Cancer
• Non-Small Cell Lung Cancer
• Pancreatic Cancer, Advanced or Metastatic

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1/2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Tasca Therapeutics

Last updated on ClinicalTrials.gov

February 18, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites